The UK and US have reached a landmark trade agreement that will ensure zero tariffs on UK medicine products entering the US market.
Key Provisions of the Deal
As part of the deal, the UK has agreed to raise funding on pharmaceuticals through the NHS. This move ensures that tariffs on these crucial exports will stay at nothing for a period of the next three years.
This development comes after earlier statements to hike import taxes on patented pharmaceutical products, with figures mentioned up to double the cost.
"This arrangement between the UK reinforces the worldwide climate for cutting-edge drugs and introduces much-needed equity to U.S.–U.K. medicine commerce," a statement noted.
Trade Significance
Drugs represent one of the the United Kingdom's largest goods shipped to the America, which is easily the biggest buyer for major British pharmaceutical firms.
Export figures show that in the 12 months prior to the third quarter, the UK shipped drugs totaling billions to the US. This amount accounted for a significant portion of total UK exports in that timeframe.
"This agreement safeguards jobs, increases funding and paves the way for the UK to become a global hub for biotech and pharma," a government official stated.
Specific UK Commitments
The agreement entails several notable pledges from the British government:
- Revised Affordability Limit: The UK will lift the cost ceiling at which it deems new therapies to be too expensive by a quarter.
- Higher Drug Budget: There is a target to double total NHS spending on drugs from 0.3% of Gross Domestic Product to 0.6% over the next decade.
- Refund Ceiling: The percentage drug companies must refund to the NHS to prevent overspending will be capped at 15%. Previously, rebates topped twenty percent.
Broader Context
The deal comes amid a long-running dispute between the sector and the UK government over spending levels and approval rates.
This friction were exacerbated by claims that US patients were charged a premium for the identical medicines than consumers in the UK and Europe.
Recently, several large pharmaceutical investments in the UK have been halted or cancelled, while major funding commitments have been announced toward projects in the United States.
A senior figure publicly accepted that the NHS must spend more on drugs, noting that its expenditure on drugs had declined as a proportion of its total funding over the last ten years.
